News coverage about Penumbra (NYSE:PEN) has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Penumbra earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the company an impact score of 42.3365879448053 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Europe Interventional Neurology/Neurovascular devices Market Growth and Outlook | Industry Forecast Report 2021 (emailwire.com)
- Form 4 Penumbra Inc For: Nov 27 Filed by: Pray James Robert (streetinsider.com)
- Arani Bose Sells 10,927 Shares of Penumbra, Inc. (PEN) Stock (americanbankingnews.com)
- Insider Selling: Penumbra, Inc. (PEN) CFO Sells 6,026 Shares of Stock (americanbankingnews.com)
- Insider Selling: Penumbra, Inc. (PEN) CEO Sells 10,000 Shares of Stock (americanbankingnews.com)
Shares of Penumbra (NYSE:PEN) traded up $0.55 during trading hours on Friday, reaching $105.90. 153,080 shares of the company were exchanged, compared to its average volume of 201,711. Penumbra has a 1 year low of $57.85 and a 1 year high of $116.35.
A number of equities analysts recently issued reports on the company. Canaccord Genuity raised their price target on Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets raised their price target on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Zacks Investment Research raised Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, BidaskClub downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research report on Friday, August 18th.
In related news, Director Thomas Wilder sold 345 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $90.20, for a total value of $31,119.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bridget O’rourke sold 429 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $106.60, for a total transaction of $45,731.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 301,079 shares of company stock valued at $31,150,834. 13.50% of the stock is owned by insiders.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
What are top analysts saying about Penumbra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Penumbra Inc. and related companies.